The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
|Videos|July 21, 2017
Treatment of BRAF Mutated Non-Small Cell Lung Cancer
Treatment of BRAF Mutated Non-Small Cell Lung Cancer
Advertisement
- 67-year-old female, former smoker (30 pack-years, quit 10 years ago) presented to her pulmonologist with increased cough, dyspnea and hemoptysis.
- Past medical history of mild COPD.
- Patient swims three times a week and is continuing normal activities.
- ECOG PS was assessed as 1.
- CT scan of chest and abdomen show a lower right lobe lung nodule with several small liver lesions.
- PET/CT scan indicated lung cancer with liver metastases.
- Core needle biopsy was performed in the liver. Pathology report showed adenocarcinoma consistent with non-small cell lung cancer (NSCLC).
- Mutation testing showed aBRAF V600Emutation.
- PD-L1 status was negative.
- Patient was started on pemetrexed and carboplatin.
- After 3 of 6 planned cycles patient showed worsening signs of dyspnea with a weight loss of 10%.
- Repeat CT scan showed progression of primary lesion.
- Patient was started on dabrafenib + trametinib.
Advertisement
Related to this article
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SOT106 Receives New FDA FTD and ODD in Sarcoma
2
Iberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trial
3
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
4
Trispecifics: A New Strategy to Prevent Antigen Escape
5